2019

A Review of Relevant Therapeutic Targets for the Management of Congestive Heart Failure in Dogs: Present and Future Directions

Jonathan P. Mochel
Iowa State University, jmochel@iastate.edu

A Review of Relevant Therapeutic Targets for the Management of Congestive Heart Failure in Dogs: Present and Future Directions

Abstract
Congestive heart failure (CHF) is a major cause of morbidity and mortality with an increasing prevalence in human and canine populations. Similar to humans, overactivation of the renin-angiotensin aldosterone system is involved in the pathophysiology of CHF in dogs. Current therapeutic strategies for the management of canine CHF include the use of RAAS inhibitors, diuretics and inodilators. The present review summarizes data from our own research on the modulation of the renin-angiotensin cascade in dogs in dogs, together with new findings (including novel therapeutic targets) from the veterinary and the human literature.

Keywords
RAAS, Canine Congestive Heart Failure, Therapeutics

A Review of Relevant Therapeutic Targets for the Management of Congestive Heart Failure in Dogs: Present and Future Directions

Jonathan P. Mochel[1], DVM, MS, Ph.D, DECVPT

Associate Professor of Quantitative Pharmacology

[1]SMART Pharmacology, Iowa State College of Veterinary Medicine. 50010, AMES, IA (USA).

Keywords: RAAS, Canine Congestive Heart Failure, Therapeutics

ABSTRACT

Congestive heart failure (CHF) is a major cause of morbidity and mortality with an increasing prevalence in human and canine populations. Similar to humans, overactivation of the renin-angiotensin aldosterone system is involved in the pathophysiology of CHF in dogs. Current therapeutic strategies for the management of canine CHF include the use of RAAS inhibitors, diuretics and inodilators. The present review summarizes data from our own research on the modulation of the renin-angiotensin cascade in dogs in dogs, together with new findings (including novel therapeutic targets) from the veterinary and the human literature.

TABLE OF CONTENTS

ABBREVIATIONS

ACE	Angiotensin-converting enzyme
AI	Angiotensin I
AII	Angiotensin II
ALD	Aldosterone
ARB	Angiotensin receptor blocker
ARNI	Angiotensin receptor neprilysin inhibitor
ASI	Aldosterone synthase inhibitor
AT1R	AII type 1 receptor
BP	Blood pressure
cGMP	Cyclic GMP
CHAT	Circadian hyper-amplitude-tension
CHF	Congestive heart failure
CKD	Chronic kidney disease
DCM	Dilated cardiomyopathy
EG	Empaglifozin
GR	Glucocorticoid receptor
HFpEF	Heart failure with preserved ejection fraction
HFrEF	Heart failure with reduced ejection fraction
HT	Hypertension
MMVD	Myxomatous mitral valve disease
MRA	Mineralocorticoid receptor antagonist
NLME	Nonlinear mixed-effects

NP	Natriuretic peptide
OM	Omecamtive mecarbil
PK	Pharmacokinetics
PD	Pharmacodynamics
PCP	Procollagen type I Carboxy-terminal Proteinase
RA	Renin activity
RAAS	Renin-angiotensin-aldosterone system
RI	Renin inhibitor
U2	Urocortin-2

Pathophysiology of Congestive Heart Failure in Dogs

Congestive heart failure (CHF) is a major cause of morbidity and mortality with an increasing prevalence in human and canine populations (Guglielmini, 2003; George et al., 2014). It is widely estimated that 10% of dogs examined by veterinarians have some form of heart disease. The two most common acquired heart disorders in dogs are degenerative mitral valve disease (DMVD, also referred to as **MMVD**) and dilated cardiomyopathy (**DCM**). Within these diseases, it is estimated that approximately 30% of dogs with MMVD and 70-80% of dogs with DCM will eventually develop CHF (Borgarelli et al., 2008; Calvert et al., 1997), suggesting that up to 1 in 20 dogs may be affected by this clinical syndrome. Prognosis for CHF in dogs ranges from 6-14 months, depending on underlying disease and other patient and comorbid factors (O'Grady et al., 2008). MMVD is characterized by thickening and shortening of the atrioventricular valves, and affects about 75% of dogs over the age of 16 (Guglielmini, 2003). While MMVD has been recognized in dogs for over a century, histopathological and clinical studies have not been able to reveal its cause or why it occurs ten times more frequently in dogs than in humans (Borgarelli & Buchanan, 2012).

In humans, left ventricular ejection fraction (EF; derived as the ratio of the stroke volume and the end-diastolic volume) is used to define two types of patient populations with heart failure (HF): HF with *reduced* (< 40%) EF (**HFrEF**) vs. HF with *preserved* EF (**HFpEF**). This distinction is key as EF is an important prognostic factor in HF, and HFpEF patients (approximately 50% of HF cases worldwide) are known to respond differently to available therapies (Clevand and Clark, 2012).

Essentially, HFpEF patients present with a degree with **diastolic dysfunction**, analogous to what is being described in dogs with **MMVD**. However, in humans, HFpEF is usually a primary diastolic dysfunction issue rather than a valvular disease causing volume overload, as seen in dogs with MMVD. At the other hand of the spectrum, HFrEF, also referred to as **systolic HF** is analogous to canine **DCM**, although DCM is primarily due to myocardial dysfunction rather than ischemic heart disease like in humans.

Noteworthily, HFpEF has been defined as a systemic syndrome, affecting multiple organ systems and rooted in immune dysregulation and systemic inflammation (Patel and Shah, 2019). Several comorbidities, including CBD, diabetes mellitus, obesity and other chronic inflammatory diseases have therefore been associated with HFpEF. This is important as the therapeutic management of HFpEF is geared towards integration of these various components. Importantly, there are currently **no approved drugs for the treatment of HFpEF**.

Similar to humans, the β-myosin heavy chain isoforms predominate in the dog myocardium (Hasenfuss, 1998), such that the excitation/contraction coupling in the myocardium of dogs appears to be similar to that in the human myocardium. More importantly, the pathophysiological cascade of renin activation, as observed in the course of CHF, is similar between dogs and humans, which motivated the choice of this animal species in the experimental work on the renin-angiotensin-aldosterone system (RAAS) and blood pressure (BP) pioneered by Guyton, Hall and co-workers (Cowley & Guyton, 1972; Guyton et al., 1972; McCaa et al., 1975; Young & Guyton, 1977; DeClue et al., 1978; Lohmeier et al., 1978; Hall et al., 1980, 1984; Wilczynski & Osmond, 1983). Renin release from the juxtaglomerular apparatus is a common compensatory mechanism to

the reduced cardiac output observed in symptomatic stages of canine and human heart failure (Watkins et al., 1976; Hall, 1991). Recognition of the dysregulation of the RAAS in the pathophysiology of CHF has led to significant medical advances (McMurray et al., 2012). Reduction of angiotensin II (AII) and aldosterone (ALD) levels is paramount to prevent life-threatening complications associated with myocardial fibrosis and systemic hypertension.

An Overview of the Renin-Angiotensin Aldosterone System: Past and Present

A Complex and Highly-Regulated Machinery

Various authors have amply reviewed the role of the RAAS in the regulation of BP and volume homeostasis (Ferrario & Strawn, 2006; Moon, 2013; Sayer & Bhat, 2014). The expression of certain RAAS components even in simple organisms like crustaceans, insects and leeches underscores the importance of the renin cascade in the control of cell volume and water homeostasis throughout evolution (De Mello, 2014). The history of the RAAS and its discovery has recently been retraced with great accuracy in a review paper by Tsukamoto & Kitakaze (2013).

A common description of the functioning of the systemic RAAS cascade begins with the release of renin from granular cells of the juxtaglomerular apparatus, in response to changes in sodium chloride concentrations, decreased renal blood flow, and sympathetic stimulation. Many studies have established that renin secretion is inversely related to renal perfusion pressure (Hackenthal et al., 1990; Bock et al., 1992), while β-adrenergic activation has been shown to stimulate renin release in several species, including the dog (Lew & Summers, 1987). **Renin** catalyzes the conversion of the precursor angiotensinogen to **angiotensin I** (AI), which in turn is converted to the **octapeptide AII**

by the angiotensin-converting enzyme (ACE) as it passes through the pulmonary capillaries. Enzymes other than ACE may contribute to the conversion of AI to AII. Chymase, cathepsin G, tonin and other proteases have been described as alternative pathways of AII production (Weber et al., 1995; Roig et al., 2000). AII is a potent vasoconstrictor with additional endocrine (e.g. ALD and arginine vasopressin secretion), neuronal (e.g. sympathetic noradrenaline release), and renal (e.g. glomerular filtration rate modulation) actions (Tsukamoto & Kitakaze, 2013). The majority of these effects are mediated through selective binding of AII to AT_1 receptors. In most cases AT_2 receptors binding elicits vasodilation, but cardiomyocyte hypertrophy and cell death have also been reported with stimulation of AT_2 receptors (Henrion et al., 2001). **Aldosterone** secretion from adrenocortical cells of the zona glomerulosa contributes to body fluid and acidobasic homeostasis via sodium, potassium and hydrogen ion exchanges in the distal renal tubules and collecting ducts of Bellini (Quinn & Williams, 1988). Note that the effect of ALD on the regulation of natriuresis and BP would be quantitatively less important than the action of AII on proximal tubular sodium reabsorption. This direct intrarenal effect of AII further results in reduced urinary flow in the tubular segments of the medulla, thereby increasing medullary osmolality and fluid reabsorption in the descending loop of Henle and the collecting ducts of Bellini (Hall, 1991).

Next to the systemic (circulatory) renin cascade, several RAAS components are also produced at the tissue level, in the heart, the vascular endothelium, or the kidneys (Danser, 1996; Danser et al., 1997). This ‘local RAAS’ functions as an autocrine or paracrine system and regulates tissue growth and repair processes. It is now recognized that the conventional renin/ACE/AII/AT_1 cascade is no longer the sole signaling pathway

of the RAAS. At least 3 new axes have recently been identified in the kidneys and other tissues (Zhuo et al., 2013). These include: i) the **ACE2/ANG$_{(1-7)}$/Mas** receptor pathway, that may play an opposing role to the **renin/ACE/AII/AT$_1$** axis (Esteban et al., 2009), ii) the prorenin/PRR/MAP kinases ERK1/2 axis, which appears to be pivotal in the development of diabetic nephropathy in rodents (Ichihara et al., 2004, 2006), and iii) the ANGIV/AT$_4$/IRAP cascade, whose implication in the regulation of BP and renal modulation remains controversial. With the discovery of these additional pathways, the action of the RAAS has been extended beyond the regulation of BP, sodium and fluid homeostasis by the AT$_1$ receptor.

RAAS Activation in Vascular Inflammation, Remodeling and Congestive Heart Failure

Excessive activation of the RAAS plays an essential role in vascular inflammation and remodeling (Pacurari et al., 2014). Animal and human studies have shown that AII possesses pro-inflammatory actions by regulating the expression of cytokines and chemokines in the kidneys, vessels and the heart (Hahn et al., 1994; Tummala et al., 1999). Consequently, chronic infusion of AII has been associated with increased BP, myocardial infiltration of inflammatory cells, and cardiac fibrosis (Qi et al., 2011). Many of these pathophysiological changes can be attributed to mechanical injury from elevated BP and AII-induced oxidative stress (Weir, 2006), and will eventually result in end-organ damage manifested by myocardial infarction, CHF, and chronic kidney disease (CKD) (Chobanian et al., 2003). The pro-inflammatory and pro-fibrotic effects of the RAAS are also mediated by ALD, which further promotes insulin resistance and vascular remodeling (Martinez, 2010; Cascella et al., 2010).

While the relation of systemic hypertension (HT) to the development of CKD has not been extensively documented in small animals, there is reasonable evidence to justify extrapolation of these considerations from human to dog patients (Lefebvre et al., 2007). In humans, the degree of activation of the renin-angiotensin aldosterone cascade is related to the severity of heart failure (Swedberg et al., 1990; MacFadyen et al., 1999). In this population of patients, AII concentrations vary from less than 10 pg/mL in mild cases of CHF, to 70 pg/mL in seriously affected individuals (Van de Wal et al., 2006). AII is viewed as a primary determinant of end-organ damage (Roig et al., 2000), while ALD is known to worsen AII tissue-damaging properties (Rocha et al., 1999). Thereof, elevated exposure to AII and ALD has been associated with a poor prognosis in multiple case studies (Roig et al., 2000; Latini et al., 2004). Swedberg et al. (1990) have found a positive correlation between mortality and levels of AII ($P < 0.05$) and ALD ($P < 0.003$) in a group of severe CHF patients. More recently, a 12 months follow-up study showed that AII was a significant predictor of death or new heart failure episodes in patients with left ventricular dysfunction (Roig et al., 2000). Likewise, high ALD concentrations were found to be a predictor of increased mortality risk that provides complementary prognostic value in a prospective cohort experiment of 294 patients with CHF of any cause and severity (Güder et al., 2007).

Compared with the depth of data from the human literature, only limited information on the relation of AII and ALD to a morbidity and mortality risk is presently available in dogs. Knowlen et al. (1983) have established a direct relationship between ALD and the clinical status of dogs suffering from heart failure. Results from Bernay et al. (2010) in a multicenter prospective trial indicate that ALD receptor antagonism decreases the risk of

cardiac death, euthanasia, or severe worsening in dogs with moderate to severe MMVD. Ovaert et al. (2010) suggest that patients with elevated AII and ALD could benefit from additional therapy with AII receptor blockers (ARBs), or MRAs. However, ALD escape has also been reported during long-term use of ARBs and MRAs (Naruse et al., 2002; Rousseau et al., 2002). In a study by Naruse et al. (2002), ALD increased above pre-treatment levels after 8 weeks of ARB administration, causing end-organ damage and left ventricular hypertrophy in rodents. In addition, results from the RALES Neurohormonal sub-study (Rousseau et al., 2002) showed a significant increase in AII and ALD over time ($P = 0.003$ and $P = 0.001$, respectively) in spironolactone-treated CHF patients.

ACE Activity is not a Reflective Measure of RAAS Suppression

ACE inhibitors have constituted a breakthrough therapeutic option in the management of cardiovascular diseases in human and veterinary patients (Pfeffer et al., 1992; BENCH Study Group, 1999). Earlier investigations on the use of benazepril in dogs have established that benazeprilat produces a complete and long-lasting inhibition of ACE. In a study by King et al. (1995), oral administrations of benazepril (0.25 mg/kg q24 h) were responsible for more than 85% inhibition of ACE during 24 hours. In addition, Toutain and Lefebvre (2004) have shown that an oral daily dose of 0.125 mg/kg benazepril causes inhibition of the entire systemic ACE pool within 48 hours.

However, results from our group (Mochel et al., 2013a, Mochel et al., 2015) demonstrate that benazeprilat triggers a marked fall in AII and ALD, but for a much **shorter period of time**, which is consistent with earlier observations in human patients (Lijnen et al., 1982; Jorde et al., 2002). According to Van de Wal et al. (2006), 45% of severe CHF patients experience **elevated AII levels independent of serum ACE activity**. In individuals with

high ACE activity, non-compliance should be considered along with inadequate dose selection as potential explanations. Yet, in patients with low measurable ACE activity, this could be related to the production of AII by up-regulation of ACE independent pathways (Fyhrquist and Saijonmaa, 2008), in response to renin activation and accumulation of AI during short and long-term use of ACE inhibitors (Geary et al., 1992). Enzymes other than ACE may contribute to the conversion of AI to AII. **Chymase**, cathepsin G, tonin and other proteases have been described as alternative pathways of AII production (Roig et al., 2000). Our findings on ALD are also in agreement with earlier reports from the veterinary (Knowlen et al., 1983; Koch et al., 1994) and human literature (Lijnen et al., 1982; Cleland et al., 1984). Because AII is a known driver of ALD biosynthesis (McCaa et al., 1980), the partial suppression of AII in ACE inhibitor-treated dogs may account for the insufficient suppression of systemic ALD levels. Moreover, the possibility of an enhanced sensitivity of the adrenal glands to AII during chronic ACE inhibitor usage cannot be discarded (Lijnen et al., 1982). Finally, like all ACE inhibitors, benazeprilat has the potential to induce natriuresis and potassium retention, which can further stimulate secretion of ALD from the adrenals.

Role of Cortisol in Disease Development

Cortisol is an endogenous glucocorticoid secreted in conditions of physiologic or pathologic stress or inflammation. Most of cortisol's physiologic actions are **genomic effects mediated by binding to intracellular glucocorticoid receptors** (**GRs**). Effects of GR stimulation on metabolic and immune pathways allow the body to withstand stress and inflammation. Specific functions of glucocorticoids include stimulation of gluconeogenesis, mobilization of protein and fat stores, stabilization of lysosomal

membranes and capillary walls, and decreased migration or function of white blood cells and other immune system components.

Although aldosterone is typically considered the "target ligand" for MRs, **cortisol actually binds MRs with the same affinity as aldosterone**, and circulating concentrations of free cortisol are 100-200 times higher than aldosterone (Levine et al., 1982; Broqvist et al., 1989). In healthy patients, cortisol simply occupies the MR binding site without activating the receptor. In non-renal tissues, such as the heart and vasculature, this tonic inhibitory binding capability is conferred by the enzyme 11β-hydroxysteroid dehydrogenase type II (11βHSD2) (Aronson, 2003). However, in inflamed or hypoxic tissues, 11βHSD2 function is impaired by abnormal oxidation-reduction potential, and **cortisol is able to activate MRs and mimic the actions of aldosterone** (Ettinger et al., 1998; Dooley et al., 2012).

In humans with chronic CHF, both cortisol and aldosterone are independent and complementary predictors of increased mortality, with high levels of *both* hormones associated with the worst prognosis (Güder et al., 2015). Another study of humans with acute decompensated CHF demonstrated that the prognostic value of these biomarkers depended on whether patients were receiving MRBs (Tidholm et al., 2005). In patients not receiving MRBs, both aldosterone and cortisol were again independent and incremental predictors of outcome. However, in MRB-treated patients, only aldosterone remained a significant predictor of mortality; cortisol was no longer associated with outcome (Tidholm et al., 2005). These findings suggest that the **pharmacologic benefit of blocking MRs** may have more to do with **blocking cortisol** than with blocking aldosterone, and that measures of RAAS activation (such as aldosterone levels) alone

may have limited value in determining whether a patient will benefit from MRBs. While previous studies have established the prognostic value of cortisol in human CHF, the effects of endogenous cortisol levels in canine CHF remain unknown.

Established Pharmacological Targets in the Treatment of Canine CHF

Inhibition of the RAAS, as part of a global therapeutic scheme to decrease AII and ALD exposure, and to lower BP for preventing, or delaying end-organ damage, has proved to be effective in human and canine CHF (Chobanian et al., 2003; Lefebvre et al., 2007). Among RAAS inhibitors, two classes of drug directly target AII through complementary modes of action: i) **ACE inhibitors** prevent the formation of AII and the degradation of bradykinin, which increases the stimulation of nitric oxide and has positive effects on endothelial function, while ii) **Angiotensin Receptor Blockers** (ARBs) selectively antagonize AII at AT_1 receptors. A theoretical advantage of ARBs lies in their ability to increase activation of the AT_2 receptor, and modulate the effects of AII breakdown products (Liu et al., 1997), while reducing the risk of ALD escape. In practice though, an escape phenomenon has also been reported during long-term use of ARBs. In a study by Naruse et al. (2002), ALD increased above pre-treatment levels after 8 weeks of ARB administration, causing end-organ damage and left ventricular hypertrophy in rodents. Although non-peptide ARBs have found extensive applications in the treatment of cardiovascular disorders in human medicine, their use in small animal patients has proven ineffective (Adams, 2009).

By decreasing systemic vascular resistance, ACE inhibitors are known to improve cardiac hemodynamics and exercise capacity in human and dog patients (Levine et al., 1984; Uretski et al., 1988; Lefebvre et al., 2007). Benazepril, enalapril, imidapril, and ramipril

229 are currently approved for use in dogs with CHF. Of note, multiple studies have shown
230 that imidapril was non-inferior to enalapril and benazepril (Amberger et al., 2004; Besche
231 et al., 2007). Benazepril hydrochloride (Fortekor®; Novartis Animal Health, Basel,
232 Switzerland), is a non-sulfhydryl prodrug which is converted *in vivo* by esterases into its
233 active metabolite, benazeprilat, a highly potent and selective inhibitor of ACE (Webb et
234 al., 1990) with well-documented effectiveness in symptomatic canine CHF (King et al.,
235 1995; Lefebvre et al., 2007). In the BENCH Study (1999), the mean survival time of
236 benazepril-treated dogs with mild to moderate CHF was improved by a factor of 2.7, as
237 compared with the placebo group (428 vs. 158 days). A significant gain in exercise
238 tolerance and clinical condition was also reported after 28 days of treatment. The
239 favorable outcome of most CHF canine patients under ACE inhibition therapy, despite a
240 potential incomplete reduction in AII and ALD, suggests that ACE inhibitors exert
241 additional beneficial effects than AII suppression in the course of heart disease (The
242 CONSENSUS Trial Study Group, 1987; Pfeffer et al., 1992). As pointed out by Brown and
243 Vaughan (1998), inhibition of bradykinin degradation, which results in a subsequent gain
244 in left ventricular relaxation and systolic dysfunction, may account for the clinical
245 effectiveness of ACE inhibitors. Along with its effect on ACE inhibition and bradykinin
246 degradation, the blood pressure-lowering action of benazepril could also drive part of the
247 reported clinical efficacy. Cardiac remodeling is a known deleterious consequence of
248 arterial hypertension (Azibani et al., 2012), and benazepril (2 mg/kg q24 h P.O, for 2
249 weeks) has been shown to reduce blood pressure significantly ($P < 0.05$) in a dog model
250 of renal hypertension (Mishina and Watanabe, 2008).

While the use of ACE inhibitors in symptomatic stages of CHF is well-accepted, data supporting their use in asymptomatic stages (ACVIM A and B) are more sparse. In a study by Kvart et al. (2002), long-term treatment with enalapril (0.25-0.5 mg q24h P.O) in 229 Cavalier King Charles with asymptomatic MMVD did not delay the onset of heart failure. Yet, another prospective study by Atkins et al. (2007) in 124 dogs (23 breeds) with MMVD (ACVIM Stage B2) did show a trend toward benefit in time to onset of CHF (primary endpoint, $P = 0.06$) and a significant improvement in all-cause mortality ($P < 0.02$) with enalapril treatment (0.45 mg/kg q24h P.O). Finally, the positive effect of ACE inhibition in preclinical MMVD (ACVIM Stage B1) was further supported by a retrospective study from Pouchelon et al. (2008). Likewise, benazepril was shown to significantly delay the time to onset of overt DCM in a retrospective analysis by O'Grady et al. (2009) including 91 Doberman Pinchers.

As opposed to ACE inhibitors, a great body of data has accumulated over the years to support the use of the inodilator **Pimobendan**, a selective inhibitor of phosphodiesterase 3, in preclinical stages of heart failure. The recently completed EPIC study enrolling 360 dogs with Stage B2 MMVD showed that chronic administration of pimobendan significantly delayed the preclinical period ($P = 0.0038$) as compared with placebo (1228 days vs. 766 days). Of note, the effect of pimobendan vs. enalapril in symptomatic stages of MMVD and DCM was compared in a pivotal double-blinded trial from the FDA (FDA, 2007). No apparent differences in the primary endpoint (treatment success) were reported between study groups and the estimated mortality (14% death) was identical between pimobendan and enalapril. Another study (QUEST) by Haggstrom et al. (2008) comparing pimobendan (0.4-0.6 mg/kg q24h P.O) and benazepril (0.25-1 mg/kg q24h P.O) in 226

dogs with MMVD found a modest benefit in survival in dogs receiving the inodilator (hazard ratio = 0.688, $P < 0.01$).

More recently, **Mineralocorticoids Receptor Antagonists** (MRAs) have also been registered for use in canine patients suffering from CHF. Although Schuller et al. (2011) could not find any significant effect of low-dose spironolactone (0.5 mg/kg q24h P.O) on survival when used as adjunct treatment to conventional CHF therapy, a subsequent study by Bernay et al. (2010) did show a significant reduction in risk or cardiac morbidity and mortality with the use of higher spironolactone dosage (2 mg/kg q24 h, P.O). In this study, spironolactone reduced by a factor of ca. 2 the risk of cardiac-related death, euthanasia, or severe worsening when used in addition to conventional therapy (ACE inhibition, plus furosemide and digoxin if required) in dogs with MMVD. These results were however disputed by Kittleson & Bonagura (2010) on the grounds of possible methodological flaws such as bias in patient categorization. In humans, MRAs have been associated with a significant reduction in mortality in human CHF patients when combined with ACE inhibitors, whereas ARBs have not (Werner et al., 2010). These positive outcomes support the current recommendation of the use of MRAs in the treatment of human CHF with reduced ejection fraction (Butler et al., 2012).

In a study by Chen et al. (2016) in humans with diastolic heart failure (NYHA Grade 1 and 2), spironolactone (40 mg q24h P.O) significantly improved clinical symptoms when associated with low-dose furosemide (20 mg q24h P.O). **Furosemide** is a cornerstone in the treatment of heart failure in human and veterinary medicine, but its use is typically associated with a significant elevation of ALD levels (Mochel and Fink, 2012). The positive effect of combined furosemide/spironolactone could therefore be related to the direct

receptor antagonism of ALD in the context of RAAS activation. **Torasemide** (also referred to as torsemide) is a recently developed loop diuretic with a more potent and long-lasting effect than furosemide (Uechi et al., 2003; Hori et al., 2007). In addition, results from the TORIC study in humans with CHF demonstrated the superiority of torasemide over other diuretics (including furosemide) on patient mortality (Cosin et al., 2002). In a short-term term clinical trial of 366 dogs with MMVD (TEST study), Chetboul et al. (2017) showed that torasemide (0.24 mg/kg q24h P.O) was associated with a 2-fold reduction in risk of reaching a composite cardiac endpoint (spontaneous cardiac death, euthanasia due to heart failure or CHF class worsening) as compared with furosemide ($P < 0.05$). Results from Lopez et al. (2004) suggest that torasemide, but not furosemide, significantly reduce myocardial fibrosis; a mechanism that they later attributed to a reduction of PCP (Procollagen type I Carboxy-terminal Proteinase) activation, an enzyme involved in Collagen type I formation (Lopez et al., 2007).

Future Directions

Chronopharmacotherapy: Making the Best Use of Available Drug Therapies

Deeper understanding of circadian rhythms can have a substantial impact on the therapeutic management of RAAS-related diseases by determining the time of drug administration that would optimize efficacy while minimizing the occurrence of adverse effects. This concept, referred to as chronotherapy, is currently being used for the treatment of human rheumatoid arthritis (Staessen et al., 1992), lung cancer (Mazzoccoli et al., 2012) and cardiovascular diseases (Nicholls et al., 1993). An increasing number of investigations on the use of ACE inhibitors in hypertension have shown a greater reduction of BP with bedtime administration as compared with morning dosing (Palatini

et al., 1992; Hermida & Ayala, 2009). Sole and Martino (2009) have demonstrated that heart and vessels growth and remodeling were dynamic and occurred more actively during the period normally allocated to sleep. In mice, administrations of the ACE inhibitor captopril at sleeping hours significantly improved cardiovascular function and reduced adverse remodeling, while no effects were reported when the drug was given during active hours of the day (Martino et al., 2011). In a study by Nozawa et al. (2006), temocapril (another ACE inhibitor) prolonged the survival of spontaneously hypertensive rats, with a maximum effect after dosing during the resting period, and a minimum effect after dosing at the active period. The authors concluded that treatment with an ACE inhibitor at night may be a more effective dosing regimen in patients with hypertension.

Another therapeutic approach in the management of heart failure and hypertension is to continuously assess not only the medical response, but also the development of adverse effects. The optimal treatment time can vary considerably between patients, as shown by the work of Watanabe et al. (2006, 2013) in hypertensive patients under losartan/hydrochlorothiazide (L/H) (angiotensin II receptor blocker/thiazide diuretics) combination therapy. In their study, L/H taken few hours before bedtime in a 61-year-old man induced circadian hyper-amplitude-tension (CHAT), a condition associated with an increased cardiovascular disease risk. For yet another patient, CHAT was exacerbated when L/H was given during the day, but was alleviated when the same dose of treatment was taken in the evening. In all instances, optimization of therapy based on the most appropriate time of drug administration should be investigated on an individual basis.

Until recently, no detailed information on the systems dynamics of the renin cascade was available in dogs. Research performed within our group presents the first description of

the chronobiology of the canine RAAS in relation to BP, renal sodium/potassium handling, and feeding schedules using a NLME modeling approach (Mochel et al., 2013a, 2014). This model-based approach provided new insights into the relation of dietary sodium to RAAS chronobiology, which would have been impossible using standard statistics. Specifically:

i) ***The amount of sodium intake*** was shown to influence the tonic (i.e. mesor) and the phasic (i.e. amplitude) secretion of renin; the greater the intake of sodium, the smaller the mesor and amplitude of RA;

ii) ***The time of food (i.e. sodium) intake*** appeared to exert a synchronizing effect on the acrophase of RA and BP oscillations, which consolidates preliminary findings from the literature (Itoh et al., 1996).

Based on our findings on the dynamics of the circulating RAAS under physiological (Mochel et al., 2013a, 2014a), and RAAS-activated conditions (Mochel et al., 2013b, 2014b), various strategies could therefore improve therapeutic management of cardiovascular diseases in dogs. Essentially, one could think of:

i) ***Adjusting the time of dosing***. In dogs, cardioactive medications are commonly given with morning food for the sake of convenience. However, results from our chronobiological investigations with morning feeding indicate that the peak RA and BP occurs in the evening and at night. Assuming that drug efficacy is maximum when the peak effect time is synchronized with the peak of the underlying biological rhythm, one would expect **optimized efficacy with bedtime dosing** and morning feeding (or vice versa);

365 *ii)* ***Adjusting dietary sodium intake***. Since high dietary sodium is thought to play
366 a role in the development of HT, cardiovascular and renal diseases in humans,
367 a common practice in veterinary cardiology was to restrict sodium intake in the
368 diet of CHF dogs. There is however no substantial evidence that elevated
369 sodium intake increases the risk of HT in dogs (see results from Anderson et
370 al., 1986 and Greco et al., 1994 showing that fluctuations in sodium intake has
371 no apparent effect on BP and heart rate), and the current recommendation is
372 to avoid highly elevated dietary salt intake, without making a specific effort to
373 restrict it (Chandler, 2008). Furthermore, because the mesor and amplitude
374 value of RA oscillations was found to be much greater in dogs fed a low-sodium
375 regime (Mochel et al., 2014b) we could assume that CHF dogs would rather
376 benefit from a normal, not a restricted-sodium diet.

377 Taken together, our results suggest that additional research on the chronobiology of the
378 RAAS is required in small animal patients to further improve therapeutic management of
379 CHF in dogs by selecting the appropriate time of treatment.

380 Learning from Human Pharmaceutical R&D

381 ***Old Targets, New Drugs***

382 Although spironolactone is relatively inexpensive, its use has been associated with
383 multiple side effects in humans, including gynecomastia in men (Mosenkis and
384 Townsend, 2004). This is due to the ability of spironolactone to bind to other steroid
385 hormone receptors. To minimize the likelihood of such effects, more selective MRAs have
386 been developed, such as **eplerenone** (2nd MRA generation) and **finerenone** (3rd MRA
387 generation). The next generation will provide even greater selectivity towards the MR,

while targeting select tissues to further improve the benefit-risk ratio of MRAs (Ames et al., 2019).

First generation **Renin Inhibitors** (RIs), such as aliskiren have shown disappointing results for the treatment of cardiovascular (ASTRONAUT and ATMOSPHERE trials) and renal diseases in humans (Gheorghiade et al., 2013; McMurray et al., 2016). The next generation of RIs is currently under development. Finally, previously developed **Aldosterone Synthase Inhibitors** (ASIs) lacked selectivity and were discontinued (Calhoun et al., 2011).

New Therapeutic Targets

1. Recently Approved Therapeutics: Sacubitril/Valsartan

Sacubitril/valsartan (Entresto®) is a first-in-class angiotensin receptor neprilysin inhibitor (**ARNI**), which upon oral administration delivers systemic exposure to sacubitril (AHU377) and valsartan, a well-established ARB recommended by established guidelines for the treatment of HF (McMurray et al., 2012; Langenickel & Dole, 2012; Yancy et al., 2013). Sacubitril is an inactive prodrug that is rapidly hydrolyzed by carboxyl esterase 1 to sacubitrilat, a pharmacologically active NEP inhibitor [23]. Lately, results of the Phase III PARADIGM-HF clinical trial comparing Entresto® with enalapril in patients with reduced ejection fraction CHF were disclosed in the New England Journal of Medicine (McMurray et al., 2014). Entresto® was found to be superior by ca. 20% to enalapril in reducing the risks of death and of hospitalization for heart failure ($P < 0.001$). Entresto® has now been approved in many countries for the treatment of HFrEF and is recommended by European and American HF guidelines (Ponikowski et al., 2016; Yancy

et al., 2016) for the treatment of chronic symptomatic HFrEF (New York Heart Association Class II–IV).

A preliminary dog study examined the effects of sacubitril/valsartan (225 and 675mg/day) vs. placebo, sacubitril (360mg/day), valsartan (900mg/day), and benazepril (5mg/day) on the dynamics of the renin-angiotensin-aldosterone system (RAAS) and the natriuretic peptide (NP) system in dogs. Beagle dogs (N = 18) were fed a low-salt diet (0.05% Na) for 15 days to model RAAS activation observed in clinical heart failure. Drugs were administered once daily during the last 10 days, while the effects on the RAAS and NPs were assessed on Day 1, 5, and 10 (Mochel et al., 2014, 2018). Compared with placebo, sacubitril/valsartan (675mg) substantially increased cGMP circulating levels, while benazepril and valsartan showed no effect. Additionally, sacubitril/valsartan (675mg) and valsartan significantly increased plasma renin activity, angiotensin I and angiotensin II concentrations. Finally, sacubitril/valsartan (both doses), and valsartan significantly decreased plasma aldosterone vs. placebo. Systemic exposure to valsartan following sacubitril/valsartan 675mg administration was similar to that observed with valsartan 900mg administration alone.

These results were later confirmed in a small prospective, randomized clinical study of sacubitril/valsartan (20 mg/kg q12h P.O) in 13 dogs with MMVD showing a significant reduction in urinary aldosterone to creatinine ratio vs. placebo (P = 0.032) (Newhard et al., 2018). These positive findings in dogs suggest that sacubitril/valsartan is a promising pharmacological candidate for increased survival in canine cardiovascular diseases.

2. Drugs Showing Encouraging Results in Human Clinical Trials

The vast majority of ongoing clinical trials in human patients with heart failure are being conducted in HFrEF. Therefore, this paragraph exclusively focuses on current advances in this patient population. A list of novel pharmacotherapeutic modalities investigated in pre-clinical and clinical HFrEF studies is provided in Selim et al. (2017).

Omecamtive Mecarbil. Omecamtive Mecarbil (OM) is different from other inotropes as its mode of action is independent of Ca^{2+} intracellular increase. As such, OM has been shown to improve myocardial systolic function without a concomitant increase in oxygen consumption (Selim et al., 2017). In the COSMIC-HF Phase II, placebo-controlled trial including 448 patients with HFrEF, OM showed a concentration-dependent improvement in myocardial function (Teerlink et al., 2016). Launching of the Phase III program was announced in the fall of 2016.

Empaglifozin. Empaglifozin (EG) is an anti-diabetic medication that selectively inhibits the sodium glucose cotransporter 2 (Heise et al., 2013), while acting as an osmotic diuretic to reduce systemic BP (Tikkanen et al., 2015). A post-hoc analysis of the EMPA-REG OUTCOME trial looking at a subgroup of 706 patients with HF at baseline showed a significantly lower rate of cardiovascular death and HF hospitalization in type 2 diabetes patients receiving EG vs. placebo (Fitchett et al., 2016). A clinical trial is currently underway to investigate the effect of EG in CHF patients with or without diabetes.

SERCA2 Activator. SERCA2 is a specialized Ca^{2+} pump that is responsible for calcium reuptake in the sarcoplasmic reticulum. The CUPID study was designed to evaluate the efficacy of gene transfer using adeno-associated virus (AAV1) for delivery

of SERCA2 cDNA in patients with HF (Jessup et al., 2011). A follow-up trial (SERCA-LVAD) is currently underway.

CD-NP. CD-NP is a synthetic NP causing vasodilation with minimal effect on BP. In addition, CD-NP has demonstrated an inhibitory effect on myocardial fibrosis in end-stage HF patients (Ichiki et al., 2014), as well as ALD production in healthy subjects (Lee et al., 2009).

Urocortin-2. Urocortin-2 (U2) is a member of the CRF (Corticotropin-Releasing Factor) family with a high affinity to the CRF receptor. U2 was shown to improve myocardial function in animal models of HF. A preliminary clinical trial of 53 patients with acute HF showed promising results (Chan et al., 2013), however larger studies in patients with chronic HF are warranted to further evaluate the benefit of U2 in CHF.

Conclusions

In conclusion, modulation of the renin-angiotensin aldosterone cascade remains the treatment of choice for management of chronic heart failure in human and veterinary medicine. Administration of therapeutic drugs at a time where they are most likely to be effective and/or best tolerated using chronobiological approaches has the potential to significantly increase the efficiency of RAAS inhibitors at no extra-cost. As shown in other therapeutic classes (Fink et al., 2012; Pelligand et al., 2016; Riviere et al., 2016; Lin et al., 2016; Bon et al., 2018), pharmacokinetic-pharmacodynamic modeling is an attractive tool to integrate the large body of information on RAAS physiology, regulation and modulation for the selection of relevant therapeutic doses (Hallow et al., 2014; Martinez et al., 2018). Canines have long been used for the preclinical testing of human

cardioactive drugs and represent an attractive spontaneous disease model to study innovative therapeutic strategies. In return, information on new therapeutic targets for CHF from human clinical trials can guide the development of future therapeutic candidates in veterinary cardiology, under the so-called 'One Health' initiative (Schneider et al., 2018).

Sacubitril/valsartan has recently been given Class I recommendation, the strongest endorsement, in updated clinical practice guidelines simultaneously released by the American College of Cardiology, the American Heart Association and the Heart Failure Society of America in the US. Guidelines now establish sacubitril/valsartan as standard of care for HFrEF. Preliminary efficacy and safety findings in disease models of RAAS activation and clinical patients are encouraging in dogs but deserves further investigation in larger patient cohorts. Another promising combination is the association of loop diuretics with aldosterone receptor antagonists, such as spironolactone. Given the proven benefit of torasemide over furosemide and the improved selectivity of the most recent MRAs, the combination of eplerenone and torasemide could be evaluated in dogs with CHF. Finally, positive findings from the COSMIC-HF program on myocardial function in HFrEF also positions Omecamtive mecarbil as an attractive target for the treatment of canine CHF.

REFERENCES

- Adams R. Peptides: angiotensin and kinins. In Riviere J, Papich M ed: Veterinary Pharmacology and Therapeutics IX, Iowa State University Press. 2009;17:429-438.
- Amberger C, Chetboul V, Bomassi E, Rougier S, Woehrlé F, Thoulon F; FIRST (First Imidapril Randomized Study) group. Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol. 2004;6(2):9-16.
- Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019 26. doi: 10.1111/jvim.15454. [Epub ahead of print].
- Anderson DE, Gomez-Sanchez C, Dietz JR. Suppression of plasma renin and aldosterone in stress-salt hypertension in dogs. Am J Physiol. 1986;251(1 Pt 2):R181-6.
- Aronson D BA. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol. 2003;91:245-248.
- Atkins CE, Keene BW, Brown WA, Coats JR, Crawford MA, DeFrancesco TC, Edwards NJ, Fox PR, Lehmkuhl LB, Luethy MW, Meurs KM, Petrie JP, Pipers FS, Rosenthal SL, Sidley JA, Straus JH. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc. 2007;231(7):1061-9.
- Azibani F, Fazal L, Chatziantoniou C, Samuel JL, Delcayre C. Hypertension-induced fibrosis: a balance story. Ann Cardiol Angeiol. 2012;61(3):150-5.
- BENCH (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol. 1999;1(1):7-18.
- Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010;24(2):331-41.
- Besche B, Chetboul V, Lachaud Lefay MP, Grandemange E. Clinical evaluation of imidapril in congestive heart failure in dogs: results of the EFFIC study. J Small Anim Pract. 2007;48(5):265-70.
- Bock HA, Hermle M, Brunner FP, Thiel G. Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int. 1992;41: 275-280.
- Bon C, Toutain PL, Concordet D, Gehring R, Martin-Jimenez T, Smith J, Pelligand L, Martinez M, Whittem T, Riviere JE, Mochel JP. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. J Vet Pharmacol Ther. 2018;41(2):171-183.
- Borgarelli M, Buchanan JW. Historical review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol. 2012;14(1):93-101.

- Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008;22(1):120-128.
- Broqvist M, Dahlström U, Karlberg BE, Karlsson E MT. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Hear J. 1989;10(12):1075-1083.
- Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411-20.
- Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail. 2012;18(4):265-81.
- Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124(18):1945-55.
- Calvert C a, Pickus CW, Jacobs GJ, Brown J. Signalment, survival, and prognostic factors in Doberman pinschers with end-stage cardiomyopathy. J Vet Intern Med. 1997;11(6):323-326.
- Cascella T, Radhakrishnan Y, Maile LA, Busby WH Jr, Gollahon K, Colao A, Clemmons DR. Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology. 2010;151(12):5851-64.
- Chan WY, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Fail. 2013;1(5):433-41.
- Chandler ML. Pet food safety: sodium in pet foods. Top Companion Anim Med. 2008;23(3):148-53.
- Chen ZH, Jiang YR, Peng JQ, Ding JW, Li S, Yang J, Wu H, Yang J. Clinical effects of combined treatment by optimal dose of furosemide and spironolactone on diastolic heart failure in elderly patients. Exp Ther Med. 2016;11(3):890-894.
- Chetboul V, Pouchelon JL, Menard J, Blanc J, Desquilbet L, Petit A, Rougier S, Lucats L, Woehrle F; TEST study investigators. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. J Vet Intern Med. 2017;31(6):1629-1642.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
- Cleland JG, Clark AL. Heart failure--does it matter whether LVEF is reduced? Lancet. 2012;380(9851):1363-5.

- Cowley AW Jr, Guyton AC. Quantification of intermediate steps in the renin-angiotensin-vasoconstrictor feedback loop in the dog. Circ Res. 1972;30(5):557-66.
- Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation. 1997;96(1):220-6.
- Danser AH. Local renin-angiotensin systems. Mol Cell Biochem. 1996;157(1-2):211-6.
- De Mello WC. Regulation of cell volume and water transport-an old fundamental role of the renin angiotensin aldosterone system components at the cellular level. Peptides. 2014;58:74-7.
- DeClue JW, Guyton AC, Cowley AW Jr, Coleman TG, Norman RA Jr, McCaa RE. Subpressor angiotensin infusion, renal sodium handling, and salt-induced hypertension in the dog. Circ Res. 1978;43(4):503-12.
- Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: From receptors and signals to membrane targets. Mol Cell Endocrinol. 2012;350(2):223-234.
- Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M, Walther T. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One. 2009;4(4):e5406.
- Ettinger S, Benitz A, Ericsson G, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc. 1998;213(11):1573.
- FDA New Drug Application. Freedom of Information Summary, VETMEDIN – Pimobendan chewable tablets for dogs. 2007 Apr 30:1-36.
- Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98(1):121-8.
- Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526-34.
- Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224-36.
- Geary KM, Hunt MK, Peach MJ, Gomez RA, Carey RM. Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. Endocrinology. 1992;131(4):1588-94.
- George J, Struthers AD, Lang CC. Modulation of the renin-angiotensin-aldosterone system in heart failure. Curr Atheroscler Rep. 2014;16(4):403.
- Gheorghiade M., Böhm M., Greene S.J., Fonarow G.C., Lewis E.F., Zannad F., Solomon S.D., Baschiera F., Botha J., Hua T.A., et al. ASTRONAUT Investigators

and Coordinators, for the Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA. 2013;309:1125.

- Greco DS, Lees GE, Dzendzel G, Carter AB. Effects of dietary sodium intake on blood pressure measurements in partially nephrectomized dogs. Am J Vet Res. 1994;55(1):160-5.
- Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115(13):1754-61.
- Guglielmini C. Cardiovascular diseases in the ageing dog: Diagnostic and therapeutic problems. Veterinary Research Communications. 2003; 27(Suppl. 1):555–560.
- Guyton AC, Coleman TG, Cowley AW Jr, Liard JF, Norman RA Jr, Manning RD Jr. Systems analysis of arterial pressure regulation and hypertension. Ann Biomed Eng. 1972;1(2):254-81.
- Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev. 1990;70: 1067-1116.
- Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124-35.
- Hahn AW, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347(2-3):178-80.
- Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr, Cross RB. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am J Physiol. 1984;246(5 Pt 2):F627-34.
- Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol. 1980;239(3):F271-80.
- Hall JE. Control of blood pressure by the renin-angiotensin-aldosterone system. Clin Cardiol. 1991;14(8 Suppl 4):IV6-21; discussion IV51-5.
- Hallow KM, Lo A, Beh J, Rodrigo M, Ermakov S, Friedman S, de Leon H, Sarkar A, Xiong Y, Sarangapani R, Schmidt H, Webb R, Kondic AG. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model. Am J Physiol Regul Integr Comp Physiol. 2014;306(9):R647-62.
- Hankins MW, Peirson SN, Foster RG. Melanopsin: an exciting photopigment. Trends Neurosci. 2008;31(1):27-36.
- Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res. 1998;39(1):60-76.
- Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, Woerle HJ, Dugi K. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising

doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013 Dec;4(2):331-45.

- Henrion D, Kubis N, Lévy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38(5):1150-7.
- Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. 2009;54(1):40-6.
- Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114(8):1128-35.
- Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006;17(7):1950-61.
- Ichiki T, Schirger JA, Huntley BK, Brozovich FV, Maleszewski JJ, Sandberg SM, Sangaralingham SJ, Park SJ, Burnett JC Jr. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol. 2014;75:199-205.
- Itoh K, Kawasaki T, Cugini P. Effects of timing of salt intake to 24-hour blood pressure and its circadian rhythm. Ann N Y Acad Sci. 1996;783, 324–5.
- Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124(3):304-13.
- Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 2002;106(9):1055-7.
- King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res. 1995;56(12):1620-8.
- Kittleson MD, Bonagura JD. Re: Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010;24(6):1245-6.
- Knowlen GG, Kittleson MD, Nachreiner RF, Eyster GE. Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure. J Am Vet Med Assoc. 1983;183(9):991-6.
- Koch J, Pedersen HD, Jensen AL, Flagstad A, Poulsen K, Bie P. Short term effects of acute inhibition of the angiotensin-converting enzyme on the renin-angiotensin

721 system and plasma atrial natriuretic peptide in healthy dogs fed a low-sodium diet
722 versus a normal-sodium diet. Zentralbl Veterinarmed A. 1994;41(2):121-7.
723 • Kvart C, Häggström J, Pedersen HD, Hansson K, Eriksson A, Järvinen AK,
724 Tidholm A, Bsenko K, Ahlgren E, Ilves M, Ablad B, Falk T, Bjerkfås E, Gundler S,
725 Lord P, Wegeland G, Adolfsson E, Corfitzen J. Efficacy of enalapril for prevention
726 of congestive heart failure in dogs with myxomatous valve disease and
727 asymptomatic mitral regurgitation. J Vet Intern Med. 2002;16(1):80-8.
728 • Langenickel TH, Dole WP (2012) Angiotensin receptor-neprilysin inhibition with
729 LCZ696: a novel approach for the treatment of heart failure. . Drug Discovery
730 Today: Therapeutic Strategies. 9 (4): e131-e9.
731 • Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP,
732 Tognoni G, Cohn JN; Val-HeFT Investigators. The comparative prognostic value
733 of plasma neurohormones at baseline in patients with heart failure enrolled in Val-
734 HeFT. Eur Heart J. 2004;25(4):292-9.
735 • Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr.
736 Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-
737 human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49(6):668-73.
738 • Lefebvre HP, Brown SA, Chetboul V, King JN, Pouchelon JL, Toutain PL.
739 Angiotensin-converting enzyme inhibitors in veterinary medicine. Curr Pharm Des.
740 2007;13(13):1347-61.
741 • Levine TB, Francis GS, Goldsmith SR, Simon AB CJ. Activity of the sympathetic
742 nervous system and renin-angiotensin system assessed by plasma hormone
743 levels and their relation to hemodynamic abnormalities in congestive heart failure.
744 Am J Cardiol1982. 49AD;7(1659-1666).
745 • Levine TB, Olivari MT, Garberg V, Sharkey SW, Cohn JN. Hemodynamic and
746 clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients
747 with congestive heart failure. Circulation. 1984;69(3):548-53.
748 • Lew R, Summers RJ. The distribution of beta-adrenoceptors in dog kidney: An
749 autoradiographic analysis. Eur J Pharmacol. 1987;140: 1-11.
750 • Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during
751 prolonged captopril treatment. Am J Cardiol. 1982;49(6):1561-3.
752 • Lin Z, Gehring R, Mochel JP, Lavé T, Riviere JE. Mathematical modeling and
753 simulation in animal health - Part II: principles, methods, applications, and value of
754 physiologically based pharmacokinetic modeling in veterinary medicine and food
755 safety assessment. J Vet Pharmacol Ther. 2016;39(5):421-38.
756 • Liu X. [Angiotensin receptors and their signal transduction]. Sheng Li Ke Xue Jin
757 Zhan. 1997;28(1):64-6.
758 • Lohmeier TE, Cowley AW Jr, DeClue JW, Guyton AC. Failure of chronic
759 aldosterone infusion to increase arterial pressure in dogs with angiotensin-induced
760 hypertension. Circ Res. 1978;43(3):381-90.
761 • López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification
762 of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic
763 heart failure. J Am Coll Cardiol. 2007;50(9):859-67.
764 • López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop
765 diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.
766 J Am Coll Cardiol. 2004;43(11):2028-35.

- MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82(1):57-61.
- Martinez FA. Aldosterone inhibition and cardiovascular protection: more important than it once appeared. Cardiovasc Drugs Ther. 2010;24(4):345-50.
- Martinez MN, Gehring R, Mochel JP, Pade D, Pelligand L. Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation. J Vet Pharmacol Ther. 2018;41(4):E68-E76.
- Martino TA, Tata N, Simpson JA, Vanderlaan R, Dawood F, Kabir MG, Khaper N, Cifelli C, Podobed P, Liu PP, Husain M, Heximer S, Backx PH, Sole MJ. The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy. J Am Coll Cardiol. 2011;57(20):2020-8.
- Mazzoccoli G, Sothern RB, Parrella P, Muscarella LA, Fazio VM, Giuliani F, Polyakova V, Kvetnoy IM . Comparison of circadian characteristics for cytotoxic lymphocyte subset in non-small cell lung cancer patients versus controls. Clin Exp Med. 2012;12, 181–94.
- McCaa RE, McCaa CS, Guyton AC. Role of angiotensin II and potassium in the long-term regulation of aldosterone secretion in intact conscious dogs. Circ Res. 1975;36(6 Suppl 1):57-67.
- McMurray J.J.V., Krum H., Abraham W.T., Dickstein K., Køber L.V., Desai A.S., Solomon S.D., Greenlaw N., Ali M.A., Chiang Y., et al. ATMOSPHERE Committees Investigators Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N. Engl. J. Med. 2016;374:1521–1532.
- McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-69.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; the PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014; doi: 10.1056/NEJMoa1409077.
- Mishina M, Watanabe T, Matsuoka S, Shibata K, Fujii K, Maeda H, Wakao Y. Diurnal variations of blood pressure in dogs. J Vet Med Sci. 1999;61(6):643-7.
- Mochel J, Burkey B, Garcia R, Peyrou M, Giraudel J, Renard D, Danhof M. First-in-class angiotensin receptor neprilysin inhibitor LCZ696 modulates the dynamics of the renin cascade and natriuretic peptides system with significant reduction of aldosterone exposure. J Am Coll Cardiol. 2014;63(12_S).
- Mochel JP, Fink M, Bon C, Peyrou M, Bieth B, Desevaux C, Deurinck M, Giraudel JM, Danhof M. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs. Chronobiol Int. 2014;31(5):715-30.

- Mochel JP, Fink M, Peyrou M, Desevaux C, Deurinck M, Giraudel JM, Danhof M. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology. Chronobiol Int. 2013;30(9):1144-59.
- Mochel JP, Fink M, Peyrou M, Soubret A, Giraudel J, Danhof M. Pharmacokinetic/Pharmacodynamic modeling of renin-angiotensin aldosterone biomarkers following angiotensin-converting enzyme (ACE) inhibition therapy with benazepril in dogs. Pharm Res. 2015;32(6):1931-46.
- Mochel JP, Peyrou M, Fink M, Strehlau G, Mohamed R, Giraudel J, Ploeger B, Danhof M. Capturing the dynamics of systemic renin-angiotensin-aldosterone system (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013;36(2):174-80.
- Mochel JP, Teng CH, Peyrou M, Giraudel J, Danhof M, Rigel DF. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Eur J Pharm Sci. 2019;128:103-111.
- Moon JY. Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension. Electrolyte Blood Press. 2013;11(2):41-5.
- Mosenkis A, Townsend RR. Gynecomastia and antihypertensive therapy. J Clin Hypertens (Greenwich). 2004;6(8):469-70.
- Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40(1):28-33.
- Newhard DK, Jung S, Winter RL, Duran SH. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. J Vet Intern Med. 2018;32(5):1555-1563.
- Nicholls MG, Richards AM, Crozier IG, Espiner EA, Ikram H. Cardiac natriuretic peptides in heart failure. Ann Med. 1993;25(6):503-5.
- Nozawa M, Sugimoto K, Ohmori M, Ando H, Fujimura A. Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther. 2006;316(1):176-81.
- O'Grady MR, O'Sullivan ML, Minors SL, Horne R. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009;23(5):977-83.
- O'Grady MR, Minors SL, O'Sullivan ML, Horne R. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med. 2008;22(4):897-904. doi:10.1111/j.1939-1676.2008.0116.x.
- Ovaert P, Elliott J, Bernay F, Guillot E, Bardon T. Aldosterone receptor antagonists: how cardiovascular actions may explain their beneficial effects in heart failure. J Vet Pharmacol Ther. 2010;33(2):109-17.
- Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360.

- Palatini P, Racioppa A, Raule G, Zaninotto M, Penzo M, Pessina AC. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther. 1992 Oct;52(4):378-83.
- Patel RB, Shah SJ. Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. Annu Rev Pharmacol Toxicol. 2019;59:41-63.
- Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. CPT Pharmacometrics Syst Pharmacol. 2016;5(11):625-635.
- Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer J, Hawkins M. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-77.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M, Document R (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 18 (8): 891-975.
- Qi G, Jia L, Li Y, Bian Y, Cheng J, Li H, Xiao C, Du J. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol. 2011;11(2):157-67.
- Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol. 1988;50:409-26.
- Riviere JE, Gabrielsson J, Fink M, Mochel J. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. J Vet Pharmacol Ther. 2016;39(3):213-23. doi: 10.1111/jvp.12278. Epub 2015 Nov 22.
- Rocha R, Chander PN, Zuckerman A, Stier CT, Jr. (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 33 (1 Pt 2): 232-7.
- Roig E, Perez-Villa F, Morales M, Jiménez W, Orús J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53-7.
- Rousseau MF, Gurné O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM; Belgian RALES Investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol. 2002;40(9):1596-601.
- Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32(1):21-32, vii.

- Schneider B, Balbas-Martinez V, Jergens AE, Troconiz IF, Allenspach K, Mochel JP. Model-Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative. CPT Pharmacometrics Syst Pharmacol. 2018;7(2):65-68.
- Schuller S, Van Israël N, Vanbelle S, Clercx C, McEntee K. Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. J Vet Pharmacol Ther. 2011;34(4):322-31.
- Selim A, Zolty R, Chatzizisis YS. The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Pharmacol Ther. 2017;178:67-82.
- Sole MJ, Martino TA. Diurnal physiology: core principles with application to the pathogenesis, diagnosis, prevention, and treatment of myocardial hypertrophy and failure. J Appl Physiol. 2009;107(4):1318-27.
- Staessen J, Guo C, De Cort P, Fagard R, Lijnen P, Thijs L, Van Hoof R, Amery A. Mean and range of the ambulatory pressure in normotensive subjects. Chin Med J (Engl). 1992;105(4):328-33.
- Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82(5):1730-6.
- Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388(10062):2895-2903.
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35.
- Tidholm A, Häggström J, Hansson K. Vasopressin, cortisol, and catecholamine concentrations in dogs with dilated cardiomyopathy. Am J Vet Res. 2005;66(10):1709-1717.
- Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420-8.
- Toutain PL, Lefebvre HP. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther. 2004;27(6):515-25.
- Tsukamoto O, Kitakaze M. It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems. Cardiovasc Drugs Ther. 2013;27(2):133-8.
- Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999;100(11):1223-9.

- Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE, et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J. 1988;116(2 Pt 1):480-8.
- Van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106(3):367-72.
- Watanabe LA, Wei M, Sun N, Kim D, Chiang CE, Ke Y, Tseng CD, Coloma R, Vala M, Massaad R, Feig P, Guptha S. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial. Curr Med Res Opin. 2006;22(10):1955-64.
- Watanabe Y, Halberg F, Otsuka K, Cornelissen G. Toward a personalized chronotherapy of high blood pressure and a circadian overswing. Clin Exp Hypertens. 2013;35(4):257-66.
- Watkins L Jr, Burton JA, Haber E, Cant JR, Smith FW, Barger AC. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest. 1976;57(6):1606-17.
- Weber KT, Sun Y, Campbell SE. Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Eur Heart J. 1995;16 Suppl N:12-8.
- Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens (Greenwich). 2006;8(2):99-105; quiz 106-7.
- Werner C, Pöss J, Böhm M. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy? Drugs. 2010;70(10):1215-30.
- Wilczynski EA, Osmond DH. Plasma prorenin in humans and dogs. Species differences and further evidence of a systemic activation cascade. Hypertension. 1983;5(3):277-85.
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2016) 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 68 (13): 1476-88.
- Young DB, Guyton AC. Steady state aldosterone dose-response relationships. Circ Res. 1977;40(2):138-42.
- Zhuo JL, Ferrao FM, Zheng Y, Li XC. New frontiers in the intrarenal Renin-Angiotensin system: a critical review of classical and new paradigms. Front Endocrinol (Lausanne). 2013;4:166